Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 109

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 109
---
RO projections do not take into

- 68 -

account any circumstances or events occurring after the date that they were prepared. As a result, there can be no assurance that the FYARRO projections will be realized, and actual results may be materially better or worse than those contemplated in the FYARRO projections. The inclusion of this information should not be regarded as an indication that Aadi’s board of directors, Aadi or Leerink Partners considered, or now considers, that actual future results will necessarily reflect the FYARRO projections. The FYARRO projections are not included in this proxy statement in order to induce any Aadi stockholder to vote in favor of the Divestiture or to influence any Aadi stockholder to make any investment decision with respect to the Divestiture. The FYARRO projections should be evaluated, if at all, in conjunction with the financial statements of Aadi and other information regarding Aadi and the FYARRO business contained in Aadi’s public filings with the SEC. Except to the extent required by applicable federal securities laws, Aadi does not intend, and expressly disclaims any responsibility, to update or otherwise revise the FYARRO projections to reflect circumstances existing after the date the FYARRO projections were prepared or to reflect the occurrence of future events or changes in general economic or industry conditions, even in the event that any of the assumptions underlying the FYARRO business are shown to be in error. In light of the foregoing factors and the uncertainties inherent in the FYARRO projections, Aadi stockholders are cautioned not to unduly rely on any of the FYARRO projections included in this proxy statement. Financial measures provided to a financial advisor are excluded from the definition of non-GAAPfinancial measures and, therefore, are not subject to SEC rules regarding disclosures of non-GAAPfinancial measures, which would otherwise require a reconciliation of a non-GAAPfinancial measure to a GAAP financial measure. Reconciliations of non-GAAPfinancial measures were not relied upon by Leerink Partners for purposes of its financial analysis as described above in the section titled “ —Opinion of Aadi Financial Advisor” or by Aadi’s board of directors in connection with their consideration of the Divestiture. Non Risk-Adjusted FYARRO Projections Set forth below is a summary of the non risk-adjusted FYARRO projections, which are select projected financial information for the FYARRO business for fiscal years 2025 through 2039 (the year in which Aadi management assumed patent protections for FYAR